Indian Diabetes Market Share, Size and Forecast 2017-2022

1

Indian Diabetes Market Report 2017 - 2022
Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Indian Diabetes Market Encouraged by Obesity and
Sedentary Lifestyle Over the past couple of
decades, diabetes has affected as many as 70
Million of the Indian population. Some of the
factors responsible for this include western
influence on dietary habits, sedentary lifestyle,
urbanisation, obesity, etc. As a result of this,
the Indian diabetes market is expected to grow at
17 during 2017-2022. Diabetes, also known as
hyperglycaemia, is caused when the glucose levels
in the blood are higher than normal. With about
70 Million people suffering from the disease,
India accounts for the worlds largest population
of diabetic patients, and this number is expected
to double within next twenty years.Obesity is the
major cause of diabetes in India which is
primarily the result ofchanging lifestyle
patterns and sudden rise in middle-class
population.After 1990s, there has been an immense
increase in the disposable incomes led by
economic growth in the country. Owing to this, a
large section of the population has adopted
western dietary patterns including food rich in
fat, sugar and calories. This, coupled with other
factors such as growing sedentary lifestyle
andlack of physical activityhave also contributed
to the rising cases of diabetes in India. The
latest report by IMARC Group titled, Indian
Diabetes Market Report Patients, Prevalence,
Oral Antidiabetics, Insulin and Diagnostics,
finds that the Indian diabetes market reached a
value of more than US 400 Million in 2016,
growing at a CAGR of nearly 19 during 2009-2016.
Further, the market is expected to reach a value
of around US 3,600 Million by 2022, growing at a
CAGR of around 17 during 2017-2022.
4
Report Description and Highlights
Report Description

5
Report Description and Highlights
Report Description

• Request sample of the report http//www.imarcgrou
  p.com/request?typereportid550flagB
• Highlights of Indian diabetes market
• India accounts for the largest population of
  diabetic patients.
• Obesity represents the major cause for diabetes.
• Improvement in the healthcare infrastructurehave
  facilitated the growth of the market.
• Mostly, healthy diet and proper exercise can help
  keeping blood sugar levels in check but in
  certain cases medication such as oral
  anti-diabetics and insulin therapy also need to
  be administered. Currently, oral anti-diabetics
  account for most of the diabetes market in India.
  Owing to increasing involvement of the government
  and non-government organisations people are being
  introduced to the importance of healthy lifestyle
  and management of non-communicable diseases.
  Moreover, an improvement in the healthcare
  infrastructure enabling the accessibility of
  diagnostics and drugs to both the urban and the
  rural population have also facilitated the growth
  of the market in the region.
• To get more information, please visit _at_
  http//www.imarcgroup.com/india-diabetes

6
Report Description and Highlights
Report Description
The report provides the details of the major
players operative in the market which include
Abbot, Sanofi, Eli Lilly, USV, Sun Pharma, etc.
The research study serves as an exceptional tool
to understand the epidemiology, market trends,
therapeutic structure, competitive structure and
the outlook of the Indian diabetes market. This
report can serve as an excellent guide for
investors, researchers, consultants, marketing
strategists and all those who are planning to
foray into the Indian diabetes market in some
form or the other. Browse Related
Reports Japan Diabetes Market _at_
http//www.imarcgroup.com/japan-diabetes-market U
K Diabetes Market _at_ http//www.imarcgroup.com/UK-d
iabetes-market
7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us